We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 42 results

  1. The usefulness of [68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI

    Purpose

    Clinical studies of PET imaging using SSTR2 agonists have demonstrated high accuracy and correlation with SSTR2 expression in meningiomas....

    Peipei Wang, Shuai Liu, ... **n Cheng in European Journal of Nuclear Medicine and Molecular Imaging
    Article 08 September 2023

  2. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE

    Purpose

    A [ 18 F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and...

    Qing **e, Teli Liu, ... Zhi Yang in European Journal of Nuclear Medicine and Molecular Imaging
    Article 25 February 2021

  3. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China

    Purpose

    Somatostatin receptor antagonists have shown promising performance for imaging neuroendocrine neoplasms. However, there is a lack of studies...

    Meixi Liu, Yuejuan Cheng, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging
    Article 10 February 2024

  4. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy

    Purpose

    Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim...

    Simone Krebs, Joseph A. O’Donoghue, ... Neeta Pandit-Taskar in European Journal of Nuclear Medicine and Molecular Imaging
    Article 06 May 2020

  5. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification

    Purpose

    Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo...

    Eric J. Meester, Erik de Blois, ... Kim van der Heiden in EJNMMI Research
    Article Open access 17 March 2021

  6. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

    Purpose of Review

    This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future...

    Martina Di Franco, Lucia Zanoni, ... Valentina Ambrosini in Current Oncology Reports
    Article Open access 06 April 2024

  7. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    Background

    The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in...

    Jean DaSilva, Clemens Decristoforo, ... Sarah Spreckelmeyer in EJNMMI Radiopharmacy and Chemistry
    Article Open access 27 October 2023

  8. Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial

    Purpose

    18 F-labelled somatostatin receptor (SSTR) analogs offer several advantages over 68 Ga in terms of yield, cost, spatial resolution and...

    Meixi Liu, Chao Ren, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging
    Article 15 June 2024

  9. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms

    Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumours derived from cells of neuroendocrine origin and can potentially arise everywhere...

    Emilia Fortunati, Giulia Argalia, ... Valentina Ambrosini in Current Treatment Options in Oncology
    Article Open access 24 March 2022

  10. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE

    Purpose

    The purpose of this study is to evaluate the diagnostic efficacy of 68  Ga-NODAGA-LM3 and 68  Ga-DOTA-LM3 and compare them with 68 Ga-DOTATATE...

    Wenjia Zhu, Ru Jia, ... Li Huo in European Journal of Nuclear Medicine and Molecular Imaging
    Article 07 December 2021

  11. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

    Purpose

    Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is...

    Simone Krebs, Neeta Pandit-Taskar, ... Joseph A. O’Donoghue in European Journal of Nuclear Medicine and Molecular Imaging
    Article 29 October 2018

  12. Hormone therapies in meningioma-where are we?

    Introduction

    Meningiomas are associated with several gonadal steroid hormone-related risk factors and demonstrate a predominance in females. These...

    Danielle F. Miyagishima, Jennifer Moliterno, ... Murat Günel in Journal of Neuro-Oncology
    Article 23 November 2022

  14. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

    Purpose

    We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR)...

    Damian Wild, Henning Grønbæk, ... Rodney J. Hicks in European Journal of Nuclear Medicine and Molecular Imaging
    Article Open access 18 September 2023

  16. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

    Purpose

    To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ 177 Lu]Lu-satoreotide tetraxetan...

    Seval Beykan Schürrle, Uta Eberlein, ... Michael Lassmann in European Journal of Nuclear Medicine and Molecular Imaging
    Article Open access 26 March 2024

  17. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

    Purpose

    Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron emission...

    Leonie Beyer, Astrid Gosewisch, ... Harun Ilhan in European Journal of Nuclear Medicine and Molecular Imaging
    Article Open access 29 April 2021

  18. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

    Background

    Somatostatin-receptor (SSTR)-targeted PET/CT provides important clinical information in addition to standard imaging in meningioma...

    Marcus Unterrainer, Sophie C. Kunte, ... Nathalie L. Albert in European Journal of Nuclear Medicine and Molecular Imaging
    Article Open access 26 June 2023
Did you find what you were looking for? Share feedback.